Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee

Osteoarthritis Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Osteoarthritis of the Knee

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00485472
• Other study ID #: SP0905
• Secondary ID: 2006-005048-97
• Status: Terminated
• Phase: Phase 2
• First received: June 12, 2007
• Last updated: September 19, 2014
• Start date: March 2007
• Est. completion date: January 2008

Study information

• Verified date: September 2011
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyHungary: National Institute of PharmacySweden: Medical Products AgencyRomania: National Medicines AgencyCzech Republic: State Institute for Drug ControlPoland: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to evaluate the effectiveness, safety and tolerability of lacosamide (LCM) 400mg/day in treating the signs and symptoms of osteoarthritis of the knee.

Description:

LCM is an investigational drug that is being studied as a treatment in male and female patients who are diagnosed with osteoarthritis of the knee and require therapeutic doses of NSAIDs, COX-2 NSAIDs and/or paracetamol. This trial will be conducted exclusively in Europe.

The study has an adaptive 3-stage group sequential design.

The trial will last a total of 17 weeks. There will be a 2 week period to wean off current medication, followed by a 4 week period where the patient will receive placebo (inactive drug) or gradually increasing doses of LCM up to the target dose of 400mg/day. The target dose or placebo will be maintained for 8 weeks followed by a 1 week reduction period then a 2 week safety follow up period.

The last subject is expected to be enrolled in December 2007.

The study was terminated based on the outcome of the planned first interim analysis, which was performed as defined in the protocol in a subset of patients. It was decided not to continue the trial. No safety concerns were identified.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 194
• Est. completion date: January 2008
• Est. primary completion date: November 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subject has symptomatic osteoarthritis of the knee diagnosed using clinical and radiographic evidence as well as ACR criteria with symptom duration of at least 6 months.

• Subject requires therapeutic dose of an NSAID, COX-2 NSAID, and/or paracetamol/acetaminophen for osteoarthritis pain of the index knee and has taken that medication at least 5 days per week for the last 4 weeks prior to the screening visit (Visit 1).

Exclusion Criteria:

• Subject is not able to withdraw NSAIDs, COX-2 NSAIDs and/or paracetamol

• Subject is taking analgesic other than NSAIDs COX-2 NSAIDs and/or paracetamol

• Subject is planning to begin or stop treatment with glucosamine and/or chondroitin during the trial

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Drug:
• lacosamide
50 or 100mg tablet, 400mg daily, for 12 weeks

Other:
• Placebo
50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
UCB Pharma

Countries where clinical trial is conducted

Czech Republic,  Germany,  Hungary,  Poland,  Romania,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of the Western Ontario and McMaster Universities (WOMAC) Pain Subscale Score (Visual Analogue Scale Version) From Baseline to the End of the 8 Week Maintenance Period	The Visual Analogue Scale (VAS) version of the WOMAC pain subscale ranges from 0 to 100, high values describe high grade of pain.	Baseline, end of 8 week Maintenance Period	No
Secondary	Change From Baseline to End of 8 Week Maintenance Period in WOMAC Physical Function Subscale Score.	The WOMAC physical function subscale score (Visual Analogue Scale version) ranges from 0 to 100, high values describe high grade of difficulty in performing daily activities.	Baseline, end of 8 week Maintenance Period	No
Secondary	Change From Baseline to End of 8 Week Maintenance Period in WOMAC Stiffness Subscale Score.	The WOMAC stiffness subscale score (Visual Analogue Scale version) ranges from 0 to 100, high values describe high grade of stiffness.	Baseline, end of 8 week Maintenance Period	No
Secondary	Change From Baseline to End of 8 Week Maintenance Period in Total WOMAC Score.	The WOMAC total score is the sum of the normalized subscale scores for pain, stiffness, and physical function and ranges from 0 to 300, high values describe high grade of impact.	Baseline, end of 8 week Maintenance Period	No
Secondary	Patient's Global Impression of Change From Baseline at the End of 8 Week Maintenance Period.	Patient's global impression of change from baseline is a score that ranges from 'very much worse' to 'very much improved'.	at the end of 8 week Maintenance Period	No
Secondary	Response at the End of 8 Week Maintenance Period Versus Baseline Based on the (Slightly Modified)Criteria of the Osteoarthritis Research Society International (OARSI) and the Outcome Measures in Rheumatology Initiative (OMERACT).	Improvement = reduction of >= 20% and >= 10 mm in both WOMAC pain and physical function subscale. Those who met the criteria in either of the subscales had improved if response to Patient's Global Impression of change from baseline was at least 'mildly improved'. High improvement = reduction of >= 50% and >= 20 mm in either of the subscales. Response = either high improvement or improvement.	Baseline, end of 8 week Maintenance Period	No
Secondary	Amount of Rescue Medication Use During 8 Week Maintenance Period.	Use of rescue medication is expressed in number of tablets equivalent to 500 mg Paracetamol per day.	during 8 week Maintenance Period	No
Secondary	Change From Baseline to End of 8 Week Maintenance Period in Perception of Pain Interference With Subject's Sleep.	Pain interference with sleep refers to patient's last evening prior to the visit and was assessed using a 100mm visual analog scale (VAS). The VAS ranges from 0 (did not interfere) to 100 (completely interfered).	Baseline, end of 8 week Maintenance Period	No
Secondary	Change From Baseline to End of 8 Week Maintenance Period in Profile of Mood States (Total Mood Disturbance Score).	Total Mood Disturbance score sums up over the domain scores regarding Tension-anxiety, Depression-ejection, Anger-hostility, Vigor-activity (was subtracted), Fatigue-inertia, Confusion-bewilderment. Domain scores were derived as sum of the respective items and range from 0 to 20. With exception of Vigor-activity high values describe bad mood.	Baseline, end of 8 week Maintenance Period	No

External Links

•   FDA Safety Alerts and Recalls
•   Product Information